but at least two hepatic metastases were left behind. The propensity to develop fasting hypoglycxmia was uninfluenced, and three-hourly feeds were necessary to prevent the occurrence of episodes with loss of consciousness, blood glucose levels after a three to four hour fast being in the region of 20-30 mg/lOOml. Prednisone in large doses was tried without effect. Therapy with diazoxide -600 mg/day, reduced to 400 mg/day after one weekwas instituted in November 1964 with immediate benefit. Normoglycemia was restored; overnight fasting was well tolerated and blood glucose levels after a twelve to fourteen hour fast were consistently between 70 and 90 mg/100 ml. Apart from nausea for two days whilst on the larger dose (600 mg/ day), there have been no untoward side-effects from this drug.
The patient returned to work in January 1965 and has been subjectively in perfect health since treatment began. His diet, appetite and weight are now (June 1965) the same as before the onset of the illness.
The results of investigations designed to determine the mode of action of diazoxide will be published in greater detail elsewhere. Volume of distribution of glucose increased 50 %. Fasting plasma insulin, which was initially high, began gradually to fall after four days on diazoxide, eventually reaching normal levels at which it has remained.
Peripheral glucose utilization, markedly impaired at first, improved with time, and was possibly the major factor contributing to the rise in the fasting blood glucose concentration, though the fall in plasma insulin, which occurred later, undoubtedly served to maintain the therapeutic response.
Fasting plasma non-esterified fatty acids (NEFA) did not rise significantly except during a short period of excessive hyperglycxemia which occurred with the larger dose of diazoxide.
These results differ from those reported by Ernesti et al. (1965) in a similar case, possibly due to their use, in addition to diazoxide, of other hyperglycemic agents, including diuretic benzothiadiazines which enhance the blood glucose raising properties of diazoxide (Wolff & Parmley 1963) , but not necessarily in the same way.
Preliminary studies in a further patient with hypoglycemia due to glycogen storage disease, and encouraging reports of the usefulness of diazoxide in the treatment of other varieties of hypoglycaemia which are unamenable to specific curative therapy (Drash & Wolff 1964) suggest that further trials of the drug, either alone or in combination with diuretic benzothiadiazines, are amply justified. Faecal fat average 1 9 g daily. Serum calcium 9 4, phosphate 3-1 mg/100 ml. Serum antibodies (Dr Deborah Doniach) were as shown in Table 1 . It has not been possible to demonstrate adrenal auto-antibodies in the patient. Treatment and progress: Improved on cortisone acetate 12-5 mg t.d.s. with later addition of fludrocortisone 0 1 mg daily. Two years later became less well again, lacking in energy, short of breath; improved on-thyroxine but noted to be losing weight and complained of 'sticky' urine and infections of toes. Glycosuria 2%. Glucose tolerance: fasting blood sugar 200 mg/100 ml; 390 mg/100 ml at one hour; 350 mg/100 ml at two hours. Diabetes not controlled by chlorpropamide 500 mg and phenformin 100 mg daily. Now receiving 40 units insulin lente daily. Also receiving thyroxine 0'2 mg daily and vitamin B12 100 pg monthly.
Comment
The association of Addison's disease and primary hypothyroidism (Schmidt's syndrome) is well known and diabetes mellitus has been reported in some cases (Carpenter et al. 1964) . The occurrence of addisonian anemia in addition to these three is unusual, although the former is commonly associated with primary hypothyroidism alone. It is tempting to regard these multiple deficiencies in this patient as autoimmune disturbances having a familial incidence. Anamia essentially normocytic -and normochromic, failing to respond to full hWmatinic therapy. Hb 52 %, reticulocytes 1 %, WBC 2,000-5,000, platelets 125,000-200,000/c.mm later falling to 30,000-90,000/c.mm. Serum bilirubin 0 7 mg/100 ml. Coombs' test negative. Marrow showed depressed erythropoiesis. Spleen, at first two fingerbreadths below costal margin, became impalpable after two months. Treated with blood transfusion whenever hvmoglobin fell below 35%; in all received 49 pints in twelve months. Methylprednisolone 4 mg t.d.s. may have reduced rate of blood loss. Eventually radioactive chromium labelled red cell studies revealed a mean red cell survival time of 30 days (normal 120 days) and a concentration of radioactivity over the spleen.
Splenectomy
July 1961 (Mr K A Moore): Spleen enlarged to twice normal. Histology revealed no significant abnormality.
Operation was followed by return of all blood elements to normal, and these have remained so without any supportive therapy other than oral iron. 
